Objective To investigate the clinical efficacy of programmed death receptor 1 (PD-1) inhibitor combined with chemotherapy or anlotinib in the treatment of advanced non-small cell lung cancer (NSCLC).
Methods The clinical data of 44 patients with advanced NSCLC from December 2020 to December 2022 were retrospectively analyzed. The patients were divided into the group A and group B (22 cases in each group) according to the treatment regimen. The group A was treated with PD-1 inhibitor combined with chemotherapy drugs, and group B was treated with PD-1 inhibitor combined with anlotinib. The clinical efficacy, survival and adverse drug reactions were compared between two groups.
Results The disease control rate in the group B was 90.91%, which was significantly higher than that in group A (59.09%) (P ＜ 0.05). There was no statistical significance in the progression-free survival and overall survival between two groups (P ＞ 0.05). During the treatment period, the incidence rates of adverse reactions (including the blood toxicity and gas trointestinal reactions) in group B were significantly less than those in group A (P ＜ 0.05).
Conclusions PD-1 inhibitor combined with antirotinib in the treatment of advanced NSCLC has a similar therapeutic effect as PD-1 inhibitor combined with chemotherapy, and the adverse reactions significantly reduce.
DownLoad: